<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860845</url>
  </required_header>
  <id_info>
    <org_study_id>DOBO-01-16</org_study_id>
    <nct_id>NCT02860845</nct_id>
  </id_info>
  <brief_title>Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections</brief_title>
  <acronym>DOBO</acronym>
  <official_title>Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clever Instruments S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a formula of boric acid and probiotics for
      vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis
      in comparison to pharmacological reference controls (depending on the suspected diagnosis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, Open, Prospective, Randomized, Controlled. Women with suspected vaginal
      infection will be randomized and distributed into two groups (control or boric acid +
      probiotics). Follow-up will last for three months and consists in 3 visits and a telephone
      interview.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2016</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 16, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score.</measure>
    <time_frame>Baseline and at 2 weeks after treatment finalization</time_frame>
    <description>Semi-quantitative scale where itching, erythema, edema, stinging and abnormal vaginal discharge are scored from 0 to 3: absent (0), mild (1), moderate (2), severe (3). Worse result is 3 (severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Level of Lactobacillus in Vaginal Flora Determined by Vaginal Cultures.</measure>
    <time_frame>Baseline and 2 weeks after treatment finalization</time_frame>
    <description>Lactobacillus spp count. in vaginal discharge at baseline and at visit 1, determined by vaginal cultures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Infections</measure>
    <time_frame>At 3 months after recruitment</time_frame>
    <description>Descriptive of the proportion of patients with vulvovaginitis recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Candidiasis</condition>
  <condition>Vaginosis, Bacterial</condition>
  <arm_group>
    <arm_group_label>Boric acid and probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boric acid with L.gasseri and L.rhamnosus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic/Antifungal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotic: Clindamicine Antifungal: Clotrimazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Boric acid and probiotics</intervention_name>
    <description>Vaginal capsules administered once a day during 7 days.</description>
    <arm_group_label>Boric acid and probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic (Clindamycin)</intervention_name>
    <description>Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.</description>
    <arm_group_label>Antibiotic/Antifungal</arm_group_label>
    <other_name>Clindamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antifungal (Clotrimazole)</intervention_name>
    <description>Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
    <arm_group_label>Antibiotic/Antifungal</arm_group_label>
    <other_name>Clotrimazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years and agreement to participate by signing the consent form.

          -  Women with clinical manifestations of acute infectious vulvovaginitis (burning,
             pruritus, erythema, oedema, and abnormal vaginal discharge).

        Exclusion Criteria:

          -  Clinical findings compatible with Chlamydia trachomatis, Neisseria gonorrhoeae or
             Trichomonas vaginalis infection.

          -  Use of anti-fungal, antibiotic or probiotic medication within last 2 weeks prior to
             the study.

          -  Patients receiving other treatment (drug, probiotics or vitamin supplements) that can
             significantly interfere with study evaluations during the 3 months of follow-up.

          -  Pregnant or high risk for pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan A Tena, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ginemed Sevilla</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ginemed Sevilla</name>
      <address>
        <city>Sevilla</city>
        <state>Andaluc√≠a</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <results_first_submitted>August 19, 2019</results_first_submitted>
  <results_first_submitted_qc>October 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02860845/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Boric Acid and Probiotics</title>
          <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Antibiotic/Antifungal</title>
          <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analyzed Patients</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Boric Acid and Probiotics</title>
          <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Antibiotic/Antifungal</title>
          <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.36" spread="8.2"/>
                    <measurement group_id="B2" value="37.7" spread="6.1"/>
                    <measurement group_id="B3" value="36.83" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, non latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score.</title>
        <description>Semi-quantitative scale where itching, erythema, edema, stinging and abnormal vaginal discharge are scored from 0 to 3: absent (0), mild (1), moderate (2), severe (3). Worse result is 3 (severe)</description>
        <time_frame>Baseline and at 2 weeks after treatment finalization</time_frame>
        <population>Subscore Sobel Score values at baseline and visit 1 (from 0 to 3)</population>
        <group_list>
          <group group_id="O1">
            <title>Boric Acid and Probiotics Baseline</title>
            <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic/Antifungal Baseline</title>
            <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
          </group>
          <group group_id="O3">
            <title>Boric Acid and Probiotics Visit 1</title>
            <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Antibiotic/Antifungal Visit 1</title>
            <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score.</title>
          <description>Semi-quantitative scale where itching, erythema, edema, stinging and abnormal vaginal discharge are scored from 0 to 3: absent (0), mild (1), moderate (2), severe (3). Worse result is 3 (severe)</description>
          <population>Subscore Sobel Score values at baseline and visit 1 (from 0 to 3)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stinging sobel score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.85"/>
                    <measurement group_id="O2" value="1.21" spread="1.06"/>
                    <measurement group_id="O3" value="0.18" spread="0.50"/>
                    <measurement group_id="O4" value="0.22" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching Sobel Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.85"/>
                    <measurement group_id="O2" value="1.58" spread="1.02"/>
                    <measurement group_id="O3" value="0.41" spread="0.80"/>
                    <measurement group_id="O4" value="0.57" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Sobel Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.93"/>
                    <measurement group_id="O2" value="0.96" spread="1.12"/>
                    <measurement group_id="O3" value="0.14" spread="0.64"/>
                    <measurement group_id="O4" value="0.17" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema Sobel Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.78"/>
                    <measurement group_id="O2" value="0.42" spread="0.72"/>
                    <measurement group_id="O3" value="0.05" spread="0.21"/>
                    <measurement group_id="O4" value="0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>abnormal vaginal discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.96"/>
                    <measurement group_id="O2" value="1.96" spread="1.08"/>
                    <measurement group_id="O3" value="0.23" spread="0.53"/>
                    <measurement group_id="O4" value="0.35" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Level of Lactobacillus in Vaginal Flora Determined by Vaginal Cultures.</title>
        <description>Lactobacillus spp count. in vaginal discharge at baseline and at visit 1, determined by vaginal cultures.</description>
        <time_frame>Baseline and 2 weeks after treatment finalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Boric Acid and Probiotics Baseline</title>
            <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic/Antifungal Baseline</title>
            <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
          </group>
          <group group_id="O3">
            <title>Boric Acid and Probiotics Visit 1</title>
            <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Antibiotic/Antifungal Visit 1</title>
            <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Level of Lactobacillus in Vaginal Flora Determined by Vaginal Cultures.</title>
          <description>Lactobacillus spp count. in vaginal discharge at baseline and at visit 1, determined by vaginal cultures.</description>
          <units>Count of Organism/counting chamber</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.59" spread="50.74"/>
                    <measurement group_id="O2" value="49.30" spread="59.77"/>
                    <measurement group_id="O3" value="81.82" spread="84.34"/>
                    <measurement group_id="O4" value="66.09" spread="77.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Infections</title>
        <description>Descriptive of the proportion of patients with vulvovaginitis recurrence</description>
        <time_frame>At 3 months after recruitment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Boric Acid and Probiotics</title>
            <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic/Antifungal</title>
            <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Infections</title>
          <description>Descriptive of the proportion of patients with vulvovaginitis recurrence</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to three months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Boric Acid and Probiotics</title>
          <description>Boric acid with L.gasseri and L.rhamnosus
Boric acid and probiotics: Vaginal capsules administered once a day during 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Antibiotic/Antifungal</title>
          <description>Antibiotic: Clindamicine Antifungal: Clotrimazol
Antibiotic (Clindamycin): Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
Antifungal (Clotrimazole): Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roser De Castellar</name_or_title>
      <organization>Laboratorios Ordesa</organization>
      <phone>+34 902105243</phone>
      <email>Roser.DeCastellar@ordesa.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

